THE SPIRIT OF VOLUNTARISM
A legacy of commitment and contribution

Proceedings of the
United States Pharmacopeial Convention
March 9–12, 1995
Washington, D.C.

Published by the Board of Trustees
United States Pharmacopeial Convention
Jerome A. Halperin, Executive Vice President
12601 Twinbrook Parkway, Rockville, Maryland 20852
## CONTENTS

### SCIENTIFIC SYMPOSIUM ........................................ 1

#### EVOLVING HEALTH CARE TECHNOLOGIES: SETTING THE STAGE FOR THE NEXT QUINQUENNIUM

- Opening Remarks—Mark Novitch, M.D., President .................. 3
- Reinventing Public Health
  - Philip R. Lee, M.D.
  - Assistant Secretary for Health
  - Department of Health and Human Services ...................... 5
- New Technologies to Transform and Save a Therapeutics/Health Care Industry in Crisis
  - W. Leigh Thompson, Jr., Ph.D., M.D.
  - Chief Scientific Officer (Retired)
  - Eli Lilly & Company ............................................. 17
- Future Technologies and Health Care:
  - Partnerships, Policy, and Panache
  - Don E. Detmer, M.D., Chair
  - Institute of Medicine
  - Board of Health Care Services .................................. 30
- International Implications of the European Union’s Impact on Standard Setting
  - Willis B. Goldbeck, Chairman
  - Institute for Alternative Futures ................................ 42
- Health-Oriented Telecommunications
  - Michael D. McDonald, M.P.H.
  - The C. Everett Koop Institute .................................... 54

### IMPLICATIONS FOR STANDARDS AND DRUG INFORMATION

- Process Standards
  - Anthony S. Lubiniecki, Sc.D.
  - Vice President and Director
  - Biopharmaceutical Manufacturing & Development
  - SmithKline Beecham ............................................. 67
Therapeutic Options
John M. Eisenberg, M.D., M.B.A.
Chairman, Department of Medicine
Physician-in-Chief
Georgetown University Medical Center ........................................... 74

An Industry Perspective on Biomaterials Availability
Barriers to Technology Access and Information
James S. Benson
Vice President for Science and Regulation
Health Industry Manufacturers Association .............................. 86

Prospects for Cell and Tissue Culture Standards
Sharon C. Northup, Ph.D., M.B.A.
Research Director
Department of Toxicology
Baxter Healthcare Corporation ........................................... 95

Use of Dietary Supplements of Botanicals and Other Substances: A New Era of Regulation
Stephen H. McNamara, Esq., Hyman, Phelps, and McNamara, P.C. ................. 110

Gene Therapy
Ronald G. Crystal, M.D., Professor
Chief of Pulmonary and Critical Care Medicine
Cornell Medical Center, New York Hospital ............................ 124

175TH ANNIVERSARY CELEBRATION .......... 139

THE SPIRIT OF VOLUNTARISM: A LEGACY OF COMMITMENT AND CONTRIBUTION

Mark Novitch, M.D., President ........................................... 141

James H. Cosgriff, Jr., M.D.
President
Medical Society of the State of New York ............................ 141

Philip Gerbino, Pharm.D.
President
Philadelphia College of Pharmacy and Science .......................... 144
Contents

Rear Admiral Harold M. Koenig
Deputy Surgeon General
United States Navy ........................................... 147

Mitsuru Uchiyama, Ph.D.
Chairman
Committee on the Pharmacopoeia of Japan
(Remarks read by Dr. Novitch) .......................... 150

Agnès Artiges, Ph.D., J.D.
Director
European Pharmacopoeia Commission .................. 151

Robin Hutton, Ph.D.
Secretary
British Pharmacopoeia Commission ...................... 153

Professor Enrico Cingolani
Secretary General
Italian Pharmacopoeia ........................................ 155

President's Remarks—Mark Novitch, M.D. .............. 157

OPEN HEARING ............................................ 163

OPEN HEARING: CONSTITUTION
AND BYLAWS

Opening Remarks
John V. Bergen, Ph.D., Trustee
Chairman, Constitution and Bylaws Committee .......... 165

Issue 1: Executive Director to Executive Vice President .... 166

Issue 2: The Officers and Board of Trustees ............... 167

Issue 3: Membership Composition .......................... 171

Issue 4: Membership: Improving Participation ............ 182

Issue 5: Recognition of USP DI Database .................. 184

Issue 6: Committee of Revision ............................ 185

Issue 7: Miscellaneous Issues .............................. 186
OPEN HEARING: RESOLUTIONS

Opening Remarks
Jordan L. Cohen, Ph.D., Trustee
Chairman, Resolutions Committee .................................. 190

Resolution 1: Membership ............................................. 194
Resolution 2: Education ............................................... 206
Resolution 3: Global Scope: Information .......................... 211
Resolution 6: Standards for Non-U.S. Articles .................. 215

HONORS LUNCHEON

Mark Novitch, M.D., President ....................................... 218
James T. Doluisio, Ph.D., Chairman, Board of Trustees ....... 218
Recognition of Honor Citation Recipients ....................... 218
Presentation of Honorary Memberships ............................ 219

OPEN HEARING: RESOLUTIONS
(CONTINUED)

Resolution 4: Expansion of Information for Rational
Therapeutic Decision Making ........................................ 224
Resolution 5: Medical Devices—Information Database ......... 230
Resolution 7: Scope of Standards .................................... 234
Resolution 8: Environmental Concerns ............................ 244
Resolution 9: Biomaterials ............................................. 247
Resolution 10: Drug Storage Standards ............................ 250
Resolution 11: Standards and Information for Gene
and Cell Therapies ................................................... 260
Resolution 12: Standards and Information for Dietary
Supplements .......................................................... 267
Resolution 13: Off-Label Uses ....................................... 279
BUSINESS SESSIONS I & II ........................................ 287

BUSINESS SESSION I

Call to Order
Mark Novitch, M.D., President .................................. 289

Initial Report of the Credentials Committee
Arthur Hull Hayes, Jr., M.D., Chairman ......................... 290

Presentation of the Minutes
Jerome A. Halperin, Secretary .................................. 291

Guest Remarks
David A. Kessler, M.D., J.D.
Commissioner of Food and Drugs
Food and Drug Administration .................................. 292

P. John Seward, M.D.
Chairman, Board of Trustees
American Medical Association .................................. 298

John A. Gans, Pharm.D.
Executive Vice President and CEO
American Pharmaceutical Association ......................... 303

Gerald J. Mossinghoff
President
Pharmaceutical Research and
Manufacturers of America ........................................ 309

President’s Address—Mark Novitch, M.D. ....................... 317

Report of the Board of Trustees
James T. Doluisio, Ph.D., Chairman .......................... 325

Report and Vote on Previously Proposed and Published
Amendments to the USPC Constitution and Bylaws
John V. Bergen, Ph.D., Chairman ................................ 333

Report of the Secretary of the Convention
Jerome A. Halperin, Secretary ................................. 354

Diane C. Cousins, Assistant Executive Director for
Practitioner Reporting Programs ............................ 357
BUSINESS SESSION II

Call to Order—Mark Novitch, M.D., President .................................. 361

Second Report of the Credentials Committee
Arthur Hull Hayes, Jr., M.D., Chairman .............................. 361

Report of the Treasurer
John T. Fay, Jr., Ph.D. .................................................. 361

Report of the Committee of Revision
Jerome A. Halperin, Chairman ........................................ 375
Lee T. Grady, Ph.D., Director,
Drug Standards Division ............................................. 382
Keith W. Johnson, Director,
Drug Information Division ............................................... 394

Report of the Resolutions Committee
Jordan L. Cohen, Ph.D., Chairman .................................. 404

Report of the Nominating Committee for
Officers and Trustees
J. Richard Crout, M.D., Chairman .................................. 411

Report of the Nominating Committee for the
General Committee of Revision
James C. Boylan, Ph.D., Chairman ................................ 413

Election of the 1995–2000 Committee of
Revision and Officers and Trustees .............................. 420

BUSINESS SESSION III ................................. 423

Call to Order—Mark Novitch, M.D., President .......... 425

Report of the Credentials Committee
Arthur Hull Hayes, Jr., M.D., Chairman ..................... 425

Final Report of the Resolutions Committee and
Vote on Resolutions
Jordan L. Cohen, Ph.D., Chairman ............................. 426
Announcement of 1995–2000 Committee of Revision Members, Convention Officers, and Board of Trustees
   James Boylan, Ph.D., Chairman, Nominating Committee ....... 466

Introduction of 1995–2000 Officers and Trustees
   Mark Novitch, M.D., President ........................................ 469

Unfinished Business, Members' Open Forum
   Jane E. Henney, M.D., President ............................... 471

Adjournment .......................................................... 479

APPENDIXES .......................................................... 481

APPENDIX I
   United States Pharmacopeial Convention Constitution
      and Bylaws as Revised, March 12, 1995 .......................... 483

APPENDIX II
   Members Present at the 1995 Quinquennial Meeting
      (by Membership Category) ....................................... 513

APPENDIX III
   Members Present at the 1995 Quinquennial Meeting
      (by Name) ................................................................ 527

APPENDIX IV
   United States Pharmacopeial Convention Committees .......... 537

APPENDIX V
   Observers Present at the 1995 Quinquennial Meeting
      (by Name) ................................................................ 539